11 October 2024
The Russian Ministry of Industry and Trade aims to substantially boost the proportion of medications from the list of vital and essential drugs (VED) that are manufactured using domestic pharmaceutical ingredients. Within six years, this figure should increase from the current 45 to 60%. This was announced by the head of the Ministry of Industry and Trade Anton Alikhanov at the Bioprom-2024 forum.
“We aim to ensure that 60% of the drugs we produce come from our own substances within the next six years. While this may not seem overly ambitious, achieving this goal will demand substantial effort,” Alikhanov remarked. “This is a step toward technological leadership and aligns with our national projects focused on achieving technological sovereignty in healthcare.”
At the moment 77% of drugs from the list of vital and essential drugs are produced by Russian pharmaceutical companies. The department plans to increase this figure to 90% in six years, the minister said. Within the framework of the federal project, a list of international non-proprietary names (INN) has already been developed, including 186 items that need to be mastered.
PrintOctober 10 – World Mental Health Day
10 October 2024
Long-Term Game: NovaMedica Experts at the Pharma Marketing Conference
10 October 2024
NovaMedica in the TOP-1000 Russian Managers Rating
28 September 2024
The Ministry of Health recommended adding 2 new drugs to the essential drugs list
11 November 2024
Russian government to allocate 770 million rubles for expanded neonatal screening
11 November 2024
Sustainability continues to steer pharmaceutical packaging market
08 November 2024
Chinese company invests 1.7 billion rubles in heparin plant in Moscow region
08 November 2024